Tom Brady Didn’t Just Enter the Market. He Entered at the Exact Moment It Changed.

Most health categories don’t scale in a straight line. They move in phases, and the transition between those phases is usually marked by one thing: attention shifting from early adopters to everyone else.

That’s what this is.

GLP-1 has already proven demand. Prescriptions have surged over the past few years, driven by medications like Ozempic and Wegovy, with some reports showing 300%+ growth in prescribing volume since 2020. At the same time, projections from firms like Morgan Stanley estimate the category could exceed $100B+ globally within the next decade, largely fueled by obesity prevalence and long-term metabolic health demand.

So no, this isn’t early anymore.

This is the point where the category stops being “high growth” and starts becoming “high competition.”

‍

What Happens Next (And Why Most Brands Misread It)

When a category crosses into mainstream awareness, the mechanics of growth change fast. Not gradually. Fast.

Here’s what typically follows within months, not years:

• New entrants flood the market, often with similar offers and positioning
• Paid acquisition costs increase as more brands compete for the same inventory
• Creative fatigue accelerates, because everything starts to look interchangeable
• Consumers become more skeptical, because they see more options than they can evaluate

We’re already seeing this in telehealth performance benchmarks.

Across DTC telehealth funnels, the average landing page still converts around 2–3%, while the top performers push past 10% by fixing messaging, structure, and friction points.

That gap is not a “nice to have.” It’s the difference between scaling profitably and getting priced out of your own acquisition channels.

‍

The Real Problem: Everyone Starts Doing the Same Thing

At this stage, most brands react in predictable ways.

They increase ad spend, launch more offers and double down on whatever worked last quarter.

It feels logical. But it also stops working.

Because once ten brands are selling the same GLP-1 access model, the user experience starts to collapse into one category-level perception. From the buyer’s perspective, the differences shrink. Now you’re not being compared to your past performance - you’re being compared to every other option in the market.

That’s where things break.

Where Telehealth Funnels Start Losing Patients

If you look closely at underperforming funnels in GLP-1 and telehealth, the issues are rarely dramatic. They’re small, repeated inefficiencies that compound under competition.

A typical breakdown looks like this:

Landing page visit → user lands but doesn’t immediately understand the offer
Click to start consult → hesitation due to unclear process or pricing
Intake form → abandonment increases as friction builds
Provider consult → drop-off from lack of urgency or trust
Payment → final hesitation due to uncertainty or perceived risk

Individually, each step feels manageable. Together, they create a funnel that leaks the majority of potential patients before conversion.

And when CAC rises, those leaks become expensive.

What the Best-Performing Brands Are Actually Doing

The brands still scaling in this environment are not doing more. They are doing specific things better, consistently.

1. They make the first 3 seconds count

Most landing pages still bury the value proposition under brand language and vague claims. The best-performing funnels lead with clarity immediately.

A strong above-the-fold section answers three questions without forcing the user to scroll:

• What is this treating?
• How does it work?
• What should I expect?

Anything less creates hesitation, and hesitation kills conversion.

2. They remove friction where it matters most

Intake forms are one of the biggest hidden conversion killers in telehealth.

Brands often try to collect everything upfront: medical history, lifestyle details, eligibility criteria. The intent is qualification. The result is abandonment.

Every additional field introduces drop-off. In many cases, moving even half of those fields post-consult can increase conversion significantly, because the user has already committed to the process.

You are not qualifying patients at that stage. You are deciding whether they continue.

3. They align messaging across the entire funnel

One of the most common breakdowns happens between ad → landing page → consult.

The ad promises a result.
The landing page explains something else.
The consult introduces new information.

That inconsistency creates doubt.

High-performing brands treat messaging as a system, not a set of assets. What the user sees in the ad is reinforced on the landing page and clarified during the consult without suprises or disconnect.

4. They build trust before asking for action

In early-stage markets, urgency can carry conversion. In mature markets, trust does.

Users want to know:

• Is this legitimate?
• What will actually happen after I start?
• What are the risks or trade-offs?

The brands that answer those questions early convert better, because they remove uncertainty before it becomes a blocker.

5. They focus on conversion before scale

When CAC starts rising, traffic is no longer the lever - conversion is. Moving from 2% to 5% conversion does more for your business than doubling your ad spend, because it directly improves acquisition efficiency and extends how far your budget can go. This is where most of the upside is now.

‍

What This Means for GLP-1 and Telehealth Operators

If you are operating in this space today, the context has changed whether you’ve adjusted for it or not. You are no longer competing in a demand-constrained market - you are competing in an attention-saturated one.

This means:

• CAC will continue to rise as more brands enter
• Differentiation will get harder as offers converge
• Trust will become the primary conversion driver

Tom Brady entering the category doesn’t create opportunity.

It marks the point where execution starts to matter more than access.

‍

Final Take: This Is Where the Market Gets Real

Every category has a moment where growth stops being easy. This is that moment for GLP-1. The brands that win from here are not the ones launching faster or spending more aggressively. They are the ones that understand how users make decisions in a crowded market and build systems around that behavior. Because at this stage, attention is not the problem. Turning that attention into patients is.

‍